Indiva Partners With Dycar Pharmaceuticals Ltd.

The company announces their newest partnership with Dycar as well as unsecured convertible debenture financing

Indiva Limited is pleased to announce a strategic partnership with Dycar Pharmaceuticals Ltd. ("Dycar") and a concurrent non-brokered unsecured convertible debenture financing of up to $4 million.


DYCAR PRODUCTION AND DISTRIBUTION PARTNERSHIP

Indiva has entered into a financing and white-label manufacturing arrangement with Dycar.  Under the terms of the letter agreement, Dycar will provide Indiva with initial non-dilutive financing of $3.1 million, and Indiva will manufacture and distribute certain Dycar-branded cannabis products from the Company's licensed facility in London, Ontario.  The financing will be repaid by the deduction of Indiva services in kind to Dycar. The letter agreement may be renewed at the option of Dycar for a minimum of two additional terms, resulting in up to $4.5 million of additional non-dilutive financing. Indiva anticipates that it will begin the production of Dycar branded products in Q1 2020.

"We are delighted to add such a high-quality partner to our B2B platform," Niel Marotta, President and Chief Executive Officer of Indiva, said.

"Dycar and Indiva are very much aligned in our shared pursuit of delivering the very best products to market. We are very excited to begin working with the Dycar team and creating new products that meet and exceed customer and consumer expectations."

Funding is expected to occur in mid-December 2019, subject to the satisfaction of customary conditions including the execution of definitive agreements and receipt of applicable third party approvals.


CONVERTIBLE DEBENTURE FINANCING

Indiva is also announcing a concurrent non-brokered unsecured convertible debenture financing of up to $4 million. The Company will issue debentures at a price of $1,000 per debenture with each debenture convertible into 5,000 Indiva common shares at a price of $0.20 per share. The debentures will receive 10% interest paid semi-annually, on June 30 and December 31, and will mature 36 months from the date of closing. 

The financing is expected to close on or around December 10, 2019, subject to the approval of the TSX Venture Exchange. Certain principals of Dycar are expected to participate in the financing

Disclaimer: Past performance is not an indicator of future performance.

Subscribe Now
& Keep Up to Date

Get the latest pot stock recommendations, cannabis news
and industry updates straight to your inbox!

Niki Mohazeb
Niki Mohazeb

Niki is a Sydney based writer, with a passion for promoting the health benefits of medicinal cannabis. Niki also enjoys researching and writing about the future of cannabis along with the many other benefits that the plant provides, such as the diverse utilities of hemp.

Leave a Reply

Your email address will not be published. Required fields are marked *